1286754-14-0 Usage
Uses
Used in Pharmaceutical Industry:
IMidazo [1,2-B] pyrazin-3-carboxylic acid ethyl ester is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its versatile chemical structure allows for the development of new drug candidates with potential therapeutic applications.
Used in Medicinal Chemistry:
IMidazo [1,2-B] pyrazin-3-carboxylic acid ethyl ester is used as a building block in the synthesis of various heterocyclic compounds. These compounds can be further modified and optimized for specific biological targets, leading to the discovery of novel therapeutic agents.
Used in Biological Research:
IMidazo [1,2-B] pyrazin-3-carboxylic acid ethyl ester has been studied for its potential biological activities, including anti-inflammatory and analgesic properties. This makes it a valuable compound for research in the development of new treatments for pain and inflammation-related disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1286754-14-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,6,7,5 and 4 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1286754-14:
(9*1)+(8*2)+(7*8)+(6*6)+(5*7)+(4*5)+(3*4)+(2*1)+(1*4)=190
190 % 10 = 0
So 1286754-14-0 is a valid CAS Registry Number.
1286754-14-0Relevant academic research and scientific papers
PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0176; 0177, (2013/06/04)
A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0121; 0122, (2013/06/28)
A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof.
